亚盛医药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918 2022-06-30 10:41
EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma 2022-06-13 07:45
ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC 2022-06-08 08:00
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL 2022-06-08 08:00
ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies 2022-06-07 11:30
ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3% 2022-06-07 11:28
ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development 2022-05-27 10:02
Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine 2022-05-18 22:06
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting 2022-04-28 08:18
AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 2022-04-14 08:28
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma 2022-03-22 09:15
Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead 2022-03-21 23:11
Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL 2022-03-15 14:52
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 2022-03-09 07:47
Ascentage Pharma Presented at the 40th Annual J.P. Morgan Healthcare Conference Reporting Steady Transition Towards a Full-Fledged Biopharma 2022-01-12 10:19
Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference 2022-01-06 08:30
ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety 2021-12-14 22:04
ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses 2021-12-14 22:04
Ascentage Pharma and Clover Biopharmaceuticals Announce Clinical Collaboration to Evaluate IAP Antagonist, APG-1387, plus the Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, for the Treatment of Peritoneal Carcinomatosis 2021-12-09 21:00
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia 2021-12-01 08:00
1 3 4 5 6 7 9